The Sagittarius Trial

Background \& Rationale: Colon cancer is a leading cause of cancer deaths, with a high recurrence rate in stage II high-risk and stage III patients due to undetectable micro-metastases. Liquid biopsy (LB) detects residual cancer DNA post-surgery and monitors treatment response. Primary Objective: Show that therapy based on tumor genetics and LB improves outcomes and quality of life for high-risk stage II and stage III colon cancer patients compared to conventional therapy. Secondary Objectives: Compare recurrence times. Evaluate side effects and quality of life. Assess cost differences. V

Trial Details

NCT ID
NCT06490536
Phase
PHASE3
Sponsor
IFOM ETS - The AIRC Institute of Molecular Oncology
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Oxaliplatin
  • Capecitabine
  • Folinic acid
  • Fluorouracil
  • Temozolomide
  • Irinotecan
Locations (sample)
  • Berlin, Germany|52.52437,13.41053
  • Biella, Biella, Italy|45.56304,8.05796
  • Brescia, Brescia, Italy|45.53558,10.21472
  • Genova, Genova, Italy|45.21604,11.87211
  • Milan, Milano, Italy|42.78235,12.59836

Key Eligibility Criteria

  • SAGITTARIUS trial written informed consent.
  • Age ≥ 18 years.
  • Histologically confirmed diagnosis of operable stage III and High-Risk stage II CC located at least 12 cm from the anal verge by endoscopy and abov…
  • Availability of the original FFPE tumor tissue.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →